ES2063161T3 - Proteinas modificadas. - Google Patents

Proteinas modificadas.

Info

Publication number
ES2063161T3
ES2063161T3 ES89810152T ES89810152T ES2063161T3 ES 2063161 T3 ES2063161 T3 ES 2063161T3 ES 89810152 T ES89810152 T ES 89810152T ES 89810152 T ES89810152 T ES 89810152T ES 2063161 T3 ES2063161 T3 ES 2063161T3
Authority
ES
Spain
Prior art keywords
modified proteins
eglines
egline
aminoacidos
byc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89810152T
Other languages
English (en)
Inventor
Markus Gerhard Dr Grutter
Dirk Heinz
Manfred Dr Liersch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCP Gen Pharma AG
Novartis AG
Original Assignee
Ciba Geigy AG
UCP Gen Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG, UCP Gen Pharma AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2063161T3 publication Critical patent/ES2063161T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8286—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for insect resistance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pest Control & Pesticides (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)

Abstract

SE PONEN A PUNTO NUEVOS MUTANTES DE EGLINA QUE SE DIFERENCIAN DE LAS EGLINAS NATURALES B Y C PORQUE EN LA ZONA DEL CENTRO ACTIVO (AMINOACIDOS 45 Y 46, LEU-ASP) HAN SIDO SUTITUIDOS UNO, DOS O TRES AMINOACIDOS.LOS MUTANTES OBTENIBLES POR MEDIO DE LA TECNICA GENETICA RECOMBINANTE MUESTRAN VALIOSAS CUALIDADES FARMACOLOGICAS.
ES89810152T 1988-03-07 1989-02-28 Proteinas modificadas. Expired - Lifetime ES2063161T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH84088 1988-03-07

Publications (1)

Publication Number Publication Date
ES2063161T3 true ES2063161T3 (es) 1995-01-01

Family

ID=4196431

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89810152T Expired - Lifetime ES2063161T3 (es) 1988-03-07 1989-02-28 Proteinas modificadas.

Country Status (20)

Country Link
US (1) US5079229A (es)
EP (1) EP0332576B1 (es)
JP (1) JP2716191B2 (es)
KR (1) KR0134377B1 (es)
AT (1) ATE103930T1 (es)
AU (1) AU623881B2 (es)
CA (1) CA1339105C (es)
DD (1) DD283645A5 (es)
DE (1) DE58907373D1 (es)
DK (1) DK107389A (es)
ES (1) ES2063161T3 (es)
FI (1) FI96116C (es)
HU (1) HU209401B (es)
IE (1) IE62993B1 (es)
IL (1) IL89496A0 (es)
NO (1) NO178870C (es)
NZ (1) NZ228208A (es)
PT (1) PT89916B (es)
TW (1) TW211522B (es)
ZA (1) ZA891679B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
US5674833A (en) * 1990-09-18 1997-10-07 Novo Nordisk A/S Detergent compositions containing protease and novel inhibitors for use therein
US5604201A (en) * 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
BR9711540A (pt) 1996-09-24 2001-06-19 Protector & Gamble Company Inibidores de protease proteìnico estabilizados e variantes dos mesmos
US7001884B2 (en) * 2001-06-18 2006-02-21 Regents Of The University Of Michigan Eglin c based drugs for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
DE3324534A1 (de) * 1983-07-07 1985-01-17 Ciba-Geigy Ag, Basel Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel
FI86744C (fi) * 1983-11-21 1992-10-12 Ciba Geigy Ag Foerfarande foer framstaellning av eglinfoereningar
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
DE3585969D1 (de) * 1984-06-14 1992-06-11 Chiron Corp Protease-inhibitoren des alpha-1-antitrypsin typs mit modifizierter aktiever stelle und deren herstellung.
HU204563B (en) * 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
GB2199582A (en) * 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor

Also Published As

Publication number Publication date
NO178870C (no) 1996-06-19
DE58907373D1 (de) 1994-05-11
IL89496A0 (en) 1989-09-10
IE890719L (en) 1989-09-07
FI96116B (fi) 1996-01-31
ATE103930T1 (de) 1994-04-15
NO890932L (no) 1989-09-08
KR0134377B1 (ko) 1998-04-20
JPH029392A (ja) 1990-01-12
HU209401B (en) 1994-05-30
FI891020L (fi) 1989-09-08
CA1339105C (en) 1997-07-29
EP0332576A3 (en) 1990-09-12
AU623881B2 (en) 1992-05-28
JP2716191B2 (ja) 1998-02-18
DD283645A5 (de) 1990-10-17
AU3095989A (en) 1989-09-07
EP0332576B1 (de) 1994-04-06
PT89916A (pt) 1989-11-10
KR890014735A (ko) 1989-10-25
NO178870B (no) 1996-03-11
DK107389D0 (da) 1989-03-06
IE62993B1 (en) 1995-03-08
FI96116C (fi) 1996-05-10
TW211522B (es) 1993-08-21
NO890932D0 (no) 1989-03-06
HUT50503A (en) 1990-02-28
ZA891679B (en) 1989-10-25
EP0332576A2 (de) 1989-09-13
NZ228208A (en) 1990-08-28
PT89916B (pt) 1994-05-31
US5079229A (en) 1992-01-07
FI891020A0 (fi) 1989-03-03
DK107389A (da) 1989-09-08

Similar Documents

Publication Publication Date Title
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
FI891716A7 (fi) HIV-proteaasi-inhibiittoreita, jotka ovat käyttökelpoisia AIDS'in hoidossa
FI911574A7 (fi) Uusia HIV-proteiineja ja -peptidejä, jotka ovat käyttökelpoisia aidsin toteamisessa, ennaltaehkäisyssä ja hoidossa
NO950939D0 (no) Defektive adenovirusvektorer og deres anvendelse i gene-terapien
DE3786592D1 (de) Transformation von trichoderma.
ES2076337T3 (es) Mejoras en y relativas a sustentadores de moqueta.
FI893962A7 (fi) HIV-proteaasi-inhibiittoreita, jotka ovat hyödyllisiä AIDS:in hoidossa
DK205388A (da) Stjerneesksplosionskonjugater og fremgangsmaade tilfremstilling deraf samt deres anvendelse
DE68907064D1 (de) Ausgleich von verlusten und fehlern bei telekinovorrichtungen.
DE3861520D1 (de) Spannungsregler und spannungsstabilisator.
AR246983A1 (es) Plasmido dna recombinante, linea celular y procedimiento para producir beta-ngf humano.
FI883940A7 (fi) Uusia HIV-proteiineja, jotka ovat käyttökelpoisia diagnostisoitaessa, ennakolta ehkäistäessä ja hoidettaessa AIDS-sairautta
DK627687A (da) Hirudinvariant
DE3684650D1 (de) Klonierung und charakterisierung des rinder-interleukin-2-gens.
FI885296A7 (fi) Rekombinantti HIV-2 polypeptidi
DE58907373D1 (de) Modifizierte Proteine.
FI882741A7 (fi) Rekombinantti-HTLV-III-proteiineja ja niiden käyttötapoja.
DK610287D0 (da) Peptider, deres fremstilling og anvendelse
IT8719551A0 (it) Plasmidi ricombinanti utili perl'espressione in bacillus di proteine eterologhe.
ATE84315T1 (de) Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen.
DK454088D0 (da) Rekombinante, ubehandlede hiv-1-proteiner og deres anvendelse
ATE130872T1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
IT8782519A0 (it) Dispositivo per l'accensione e/o spegnimento di uno o piu'bruciatori.
DK431588D0 (da) Aryloxy(eller thio)-aminopyriminer, fremgangsmaadertil deres fremstilling samt deres anvendelse
DE3873255D1 (de) Methoden und praeparate zur vorbeugung von ulcera.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 332576

Country of ref document: ES